Exelixis Inc
NASDAQ:EXEL

Watchlist Manager
Exelixis Inc Logo
Exelixis Inc
NASDAQ:EXEL
Watchlist
Price: 41.355 USD -0.95% Market Closed
Market Cap: 11.3B USD

EV/EBIT
Enterprise Value to EBIT

12.7
Current
15.9
Median
4.5
Industry
Lower than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
12.7
=
Enterprise Value
10.3B USD
/
EBIT
814.5m USD
EBIT Growth EV/EBIT to Growth
US
Exelixis Inc
NASDAQ:EXEL
Average EV/EBIT: 18.7
12.7
21%
0.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 049.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.4
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -551.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.2
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -334.8 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
13
2-Years Forward
EV/EBIT
11.1
3-Years Forward
EV/EBIT
8.4